Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Andrew R. Heyer, a director at biote Corp. (NASDAQ:BTMD), recently made significant acquisitions of the company’s Class A common stock. On March 17, Heyer purchased a total of 75,000 shares, with the transactions valued at approximately $296,042. The shares were acquired at prices ranging from $3.9465 to $3.9476 per share. Since then, the stock has shown strong momentum, currently trading at $4.23, representing a notable 37% surge in the past week. InvestingPro analysis indicates analysts see further upside potential, with price targets ranging from $6 to $9.
The transactions were executed in two separate purchases. The first involved 50,000 shares, while the second included 25,000 shares. Following these acquisitions, Heyer’s direct holdings now total 1,523,513 shares. Additionally, Heyer has indirect holdings through various trusts and investment management entities, reflecting his extensive involvement with the company. InvestingPro subscribers can access comprehensive insider trading analysis and 7 additional key insights about BTMD’s current market position.
These transactions highlight Heyer’s continued confidence in biote Corp., a company specializing in medicinal chemicals and botanical products. The company maintains a strong financial health score according to InvestingPro metrics, with a market capitalization of $149.4 million and robust gross margins of 70%.
In other recent news, BioTE Corp reported its fourth-quarter 2024 earnings, which revealed a slight miss on earnings per share (EPS) and revenue forecasts. The company posted an EPS of $0.10, falling short of the $0.11 forecast, while revenue was reported at $49.8 million, below the expected $51.29 million. Following this announcement, Jefferies revised BioTE’s stock price target to $6.80 from $9.24, maintaining a Buy rating, despite sales and EBITDA falling short of expectations. Truist Securities also adjusted its outlook, lowering the price target to $7.00 from $9.00, yet reaffirmed a Buy rating, citing operational challenges related to new software implementation.
BioTE’s board and CEO demonstrated confidence in the company’s strategy by purchasing approximately 260,000 shares of common stock. Despite challenges, analysts from Jefferies and Truist Securities expressed optimism about BioTE’s long-term prospects, with expectations of growth returning as software-related issues are resolved. The company’s guidance for 2025 anticipates revenue growth of 2-5%, though this is below prior expectations. BioTE also launched the BioTRx wellness platform and expanded its manufacturing capabilities, aiming to strengthen its competitive position in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.